FDA Approves First New Essential Thrombocythemia Drug in 29 Years
Source Summary
The FDA approved ropeginterferon alfa-2b (Besremi) injection for treating adults with essential thrombocythemia, marking the first new therapy for this chronic blood cancer since anagrelide's approval in 1997. The approval represents a significant advancement in treatment options for the condition.
Why it matters
This approval ends a 29-year gap in new treatment options for essential thrombocythemia patients, providing physicians with an alternative therapy for managing this chronic blood disorder.
